Sentence examples for trial for testing from inspiring English sources
Some doctors criticized the organizers of the trial for testing Lucentis rather than another Genentech drug, Avastin, which works in the same way as Lucentis.
A two-stage adaptive procedure is developed in order to determine the sample size and the decision rule for the pivotal trial, for testing average bioequivalence using the two one-sided test (TOST).
The Basement provided the perfect trial for testing the friends-without-benefits relationship Amber and I had forged.
It was surprisingly hard to collect public data for this study as we required trials of at least 20 human subjects with a defined clinical binary outcome, i.e. (i) responders and non-responders, (ii) at least some detectable difference in gene expression at baseline between the two groups and (iii) the availability of a similar but entirely independent trial for testing purposes.
Our criteria for inclusion were (i) a dataset of at least 20 human subjects with a defined clinical binary outcome, i.e. responders and non-responders, (ii) at least some detectable difference in gene expression at baseline between the two groups and (iii) the availability of a similar but entirely independent trial for testing purposes.
Now consider the design of a two-stage phase II trial for testing H0: S(x*) = S0(x*), where x* denotes the survival time of interest and S denotes the survival function which can be estimated as described above (or by using the Kaplan-Meier estimator).
There is a dual focus on how to design trials for testing both safety and efficacy.
NEW YORK, NY (August 8, 2016) — A vaccine developed at Weill Cornell Medicine and NewYork-Presbyterian to blunt the effects of cocaine has advanced to clinical trials for testing in humans.
This book also discusses the challenges related to the design of clinical trials for testing the safety and efficacy of these innovative approaches.
By so doing, the number of trials for testing various ingredient formulae can be reduced, minimizing the ingredient waste.
We conclude that there is sufficient preclinical data to give serious consideration to Phase I trials for testing the antisense ODNs, first and later the AAV.
